SCHEMBL9904372

SCHEMBL9904372

COC(=O)c1ccc2c(c1)c(I)cn2C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.43
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 1/20 0.38
KDM4E B2RXH2 2/20 0.38
KIF11 P52732 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
XDH P47989 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143209 0.90 RAB9A (0.39) HTR6MAPTL3MBTL1MEN1KMT2A
SCHEMBL9901232 0.87 HTR6 (0.45) HTR6L3MBTL1MEN1KMT2AGABRG2
SCHEMBL9904834 0.86 HTR6 (0.44) HTR6L3MBTL1MEN1KMT2ANPC1
SCHEMBL25272713 0.85 HTR6 (0.43) HTR6MAPTL3MBTL1MEN1KMT2A
SCHEMBL17442691 0.85 HTR6 (0.43) HTR6MAPTL3MBTL1MEN1KMT2A
SCHEMBL14439422 0.84 HTR6 (0.42) HTR6MAPTL3MBTL1MEN1KMT2A
SCHEMBL20337590 0.83 KMT2A (0.43) HTR6MAPTL3MBTL1MEN1KMT2A
SCHEMBL29942639 0.82 AKR1C3 (0.47) HTR6L3MBTL1RAB9AKDM4EALDH1A1
SCHEMBL14304582 0.82 AKR1C3 (0.47) HTR6L3MBTL1RAB9AKDM4EALDH1A1
SCHEMBL16972300 0.81 HTR6 (0.46) HTR6L3MBTL1MEN1KMT2AGABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 HTR6 4372/4885MAPT 3618/4885L3MBTL1 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.